shionogi

A World-Class Two-Way Player Brings Fresh Energy to a Storied Tradition

Founded in 1949, the SHIONOGI Rainbow Storks are now in their 78th year. The team is led by Head Coach Hikaru Matsuda, one of Japan's top softball players. During his playing career, he reached the ...
shionogi

SHIONOGI Journal

Researchers on One Health and the Proper Use of Medications: Behind the Scenes of Rare Species Conservation and Infectious Disease Control ...
shionogi

Infectious Diseases

Shionogi is working to address major infectious disease challenges through scientific expertise, responsible policy engagement and a long-standing focus on patients. Infectious diseases continue to ...
shionogi

抗新型コロナウイルス薬 エンシトレルビル フマル酸の COVID-19の曝露後発症予防における欧州での承認取得について

塩野義製薬株式会社（本社：大阪市北区、代表取締役会長兼社長 CEO：手代木 功、以下「塩野義製薬」）は、抗新型コロナウイルス薬エンシトレルビル フマル酸（日本での製品名：ゾコーバ ...
shionogi

「ブイタマー®クリーム」の国内における小児（12歳未満）アトピー性皮膚炎に対する 用法・用量追加の製造販売承認取得について

塩野義製薬株式会社（本社：大阪市北区、代表取締役会長兼社長CEO：手代木 功、以下「塩野義製薬」）と、SHIONOGIグループの鳥居薬品株式会社（本社：東京都中央区、代表取締役社長：近藤 ...
shionogi

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure

Application is based on results from SCORPIO-PEP, the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing COVID-19 following exposure to an infected individual ...
shionogi

Xocova® (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System

OSAKA, Japan, November 22, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today ...
shionogi

Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, an Investigational Oral Antiviral for COVID-19

OSAKA, Japan, April 4, 2023 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced ...
shionogi

(Corrections) Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.) hereby announces that there have been corrections made to the above-mentioned disclosure material ...
shionogi

Shionogi Announces Global Phase 3 Trial Demonstrates Post-Exposure Prophylactic Use of Ensitrelvir Prevents Symptomatic COVID-19

OSAKA, Japan, October 29, 2024 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today ...
shionogi

中期経営計画 STS2030 Revision（2023～2030年度）

このページでは2023年度～2030年度の中期経営計画「STS2030 Revision」について紹介します。 SHIONOGIは2020年6月に、SHIONOGI Group Vision（2030年Vision）を掲げ、実現に向けた戦略である中期経営計画 ...
shionogi

Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)

OSAKA, Japan, April 2, 2026 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced ...